Oleanz Plus Tablet is a combination pharmaceutical formulation containing Fluoxetine 20mg and Olanzapine 5mg, indicated for the treatment of major depressive disorder with psychotic features and treatment-resistant depression. Fluoxetine, a selective serotonin reuptake inhibitor (SSRI), enhances serotonergic activity in the central nervous system by inhibiting serotonin reuptake, thereby improving mood and alleviating depressive symptoms. Olanzapine, an atypical antipsychotic, exerts its therapeutic effects through antagonism of dopamine and serotonin receptors, contributing to the reduction of psychotic symptoms and mood stabilization. The synergistic action of these agents provides an effective approach for patients who do not respond adequately to monotherapy. Oleanz Plus is typically administered orally once daily, with dosage adjustments based on clinical response and tolerability. Common adverse effects may include weight gain, sedation, dry mouth, and gastrointestinal disturbances. Caution is advised in patients with a history of cardiovascular disease, diabetes, or seizure disorders. Regular monitoring of metabolic parameters and mental status is recommended during treatment. This combination should be prescribed and supervised by a healthcare professional experienced in managing complex psychiatric conditions to optimize therapeutic outcomes and minimize potential risks.